BRIEF-SUPERVALU says Rob Woseth to assume additional position of interim CFO
* Supervalu inc - rob woseth, executive vice president, chief strategy officer, will assume additional position of interim chief financial officer
ZURICH, March 31 Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday, reporting it controlled 77.2 percent of the voting rights after the main offer period.
The price of the offer, which J&J announced on Jan. 26, was $280 per share for Actelion. It said it expected the transaction to close in the second quarter.
J&J has said it intends to delist Actelion, while a new research and development company being spun out of Actelion, to be called Idorsia and led by Actelion founder Jean-Paul Clozel, will have a separate Swiss listing. (Reporting by Michael Shields; editing by Brenna Hughes Neghaiwi)
* Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc
* Wabco signs global long-term supply agreement with daimler trucks for additional automated manual transmission control technology